FindTrial
Sign In

Tebotelimab

BIOLOGICAL2 trials

Sponsors

MacroGenics

Conditions

Gastric CancerGastroesophageal Junction CancerHER2-positive Gastric CancerHead and Neck CancerHead and Neck NeoplasmsHead and Neck Squamous Cell Carcinoma

Phase 2

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
CompletedNCT04082364
MacroGenicsGastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
Start: 2019-09-30End: 2025-03-25Updated: 2025-06-08
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
TerminatedNCT04634825
MacroGenicsHead and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
Start: 2021-03-17End: 2022-07-29Updated: 2023-12-20

Related Papers

Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Journal of Clinical Oncology2022-06-013 citations
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Journal for ImmunoTherapy of Cancer2022-04-01130 citations
Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).
Journal of Clinical Oncology2021-01-206 citations
MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma
Future Oncology2020-12-0296 citations
Antibodies to watch in 2020.
2020-01-01328 citations